Literature DB >> 25534792

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity).

Lauren Stevenson1, Lakshmi Amaravadi, Heather Myler, Laura Salazar-Fontana, Boris Gorovits, Susan Kirshner, Li Xue, Fabio Garofolo, Stephen C Alley, Theingi Thway, Alison Joyce, Surendra Bansal, Chris Beaver, Annik Bergeron, Xiao-Yan Cai, Laura Cojocaru, Binodh DeSilva, Isabelle Dumont, Eric Fluhler, Stephanie Fraser, Dominique Gouty, Swati Gupta, Sam Haidar, Roger Hayes, Benno Ingelse, Akiko Ishii-Watabe, Surinder Kaur, Lindsay King, Omar Laterza, Sheldon Leung, Ann Lévesque, Mark Ma, Corinne Petit-Frere, Renuka Pillutla, Mark Rose, Gary Schultz, John Smeraglia, Steven Swanson, Albert Torri, Faye Vazvaei, Jason Wakelin-Smith, Amanda Wilson, Eric Woolf, Tong-Yuan Yang.   

Abstract

The 2014 8th Workshop on Recent Issues in Bioanalysis (8th WRIB), a 5-day full immersion in the evolving field of bioanalysis, took place in Universal City, California, USA. Close to 500 professionals from pharmaceutical and biopharmaceutical companies, contract research organizations and regulatory agencies worldwide convened to share, review, discuss and agree on approaches to address current issues of interest in bioanalysis. The topics covered included both small and large molecules, and involved LCMS, hybrid LBA/LCMS, LBA approaches and immunogenicity. From the prolific discussions held during the workshop, specific recommendations are presented in this 2014 White Paper. As with the previous years' editions, this paper acts as a practical tool to help the bioanalytical community continue advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2014 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations for Large molecules bioanalysis using LBA and Immunogenicity. Part 1 (Small molecules bioanalysis using LCMS) and Part 2 (Hybrid LBA/LCMS, Electronic Laboratory Notebook and Regulatory Agencies' Input) were published in the Bioanalysis issues 6(22) and 6(23), respectively.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25534792     DOI: 10.4155/bio.14.283

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  5 in total

Review 1.  Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?

Authors:  Andrew P Mayer; Charles S Hottenstein
Journal:  AAPS J       Date:  2015-12-15       Impact factor: 4.009

2.  Feasibility of Singlet Analysis for Ligand Binding Assays: a Retrospective Examination of Data Generated Using the Gyrolab Platform.

Authors:  Tracey H Clark; Phillip D Yates; Allison Given Chunyk; Alison P Joyce; Aidong Wu; Petar Pop-Damkov; Yiqun Zhang; Elizabeth A Dreher; Laurie A Tylaska; Jo-Ann A Wentland; Kathleen B Pelletier; Lindsay E King; Chad A Ray
Journal:  AAPS J       Date:  2016-07-11       Impact factor: 4.009

3.  Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography.

Authors:  Parul Gupta; Jo-Ann Wentland; Mauricio Leal; Dangshe Ma; Rachel Roach; Antonio Esparza; Lindsay King; Mary E Spilker; Cedo Bagi; Christopher T Winkelmann; Anand Giddabasappa
Journal:  Oncotarget       Date:  2017-07-26

Review 4.  Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.

Authors:  A Trivedi; S Stienen; M Zhu; H Li; T Yuraszeck; J Gibbs; T Heath; R Loberg; S Kasichayanula
Journal:  Clin Transl Sci       Date:  2017-03-15       Impact factor: 4.689

5.  Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.

Authors:  Ellen Q Wang; Jack F Bukowski; Carla Yunis; Charles L Shear; Paul M Ridker; Pamela F Schwartz; Daniel Baltrukonis
Journal:  BioDrugs       Date:  2019-10       Impact factor: 5.807

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.